Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCAR + SCL
- Development stage
- Unknown
- Lead developer
- Formula 1
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
GCAR + SCL is an investigational combination immunotherapy developed by Exuma Biotechnology for the treatment of Large B-Cell Lymphoma (LBCL). The therapy combines GCAR, a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen, with SCL, an mRNA-lipid nanoparticle (LNP) designed to enhance or regulate CAR-T cell activity. GCAR provides the primary therapeutic effect by engineering T cells to recognize and eliminate CD19-positive malignant B cells. The SCL component is intended to modulate the CAR-T cells' persistence, potency, or safety profile. This dual-component approach aims to improve the efficacy and durability of responses in patients with aggressive B-cell lymphomas. It is currently being evaluated in Phase 1/2 clinical trials.
- Other names
- GCAR plus SCLCD19-CAR-T cell therapy plus SCL mRNA LNPCD-19-CAR-T cell therapy plus SCL mRNA LNPCD 19-CAR-T cell therapy plus SCL mRNA LNP
02
Targets
Beyond the preview
Go deeper on GCAR + SCL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCAR + SCL.